RLIP depletion suppresses ovarian cancer growth and metastasis.

Key findings of this study with potential clinical relevance include:• RLIP is an attractive therapeutic target with the ability to suppress human OC at multiple stages of development.• Reducing RLIP levels significantly inhibits OC cell growth and enhances apoptosis compared with controls.• RLIP blockade/depletion may serve as a broad-spectrum therapeutic strategy that remains effective regardless of common pathway differences among OC subtypes.• This is the first evidence from integrated in vitro and in vivo studies demonstrating the strong therapeutic promise of RLIP-targeting agents for treating metastatic OC.